Sertoli-Leydig Cell TumorSymptoms, Doctors, Treatments, Advances & More
Learn About Sertoli-Leydig Cell Tumor
Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.
Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor
The exact cause of this tumor is not known. Changes (alterations) in genes may play a role.
SLCT occurs most often in young women 20 to 30 years old. But the tumor can occur at any age.
The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.
These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:
- A deep voice
- Enlarged clitoris
- Facial hair
- Loss in breast size
- Stopping of menstrual periods
Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.
Surgery is done to remove one or both ovaries.
If the tumor is at an advanced stage, chemotherapy or radiation therapy may be done after surgery.
Aurora Gynecologic Oncology
Scott Kamelle is an Oncologist practicing medicine in West Allis, Wisconsin. Dr. Kamelle is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction. Dr. Kamelle is board certified in American Board Of Obstetrics & Gynecology, Gynecologic Oncology.
Intermountain Health West End Clinic Gynecologic Oncology
Dr. Petersen was born and raised in Arvada, Colorado. She earned her undergraduate degree from the University of Colorado - Boulder and her Doctor of Medicine from the University of Colorado Health Sciences Center in Denver. Dr. Petersen completed an Internal Medicine Internship with the University of Utah – Salt Lake City and an Obstetrics and Gynecology Residency with Banner Good Samaritan Medical Center in Phoenix, Arizona. She completed a Gynecologic Oncology Fellowship with the University of California, Davis Medical Center. A board-certified provider, Dr. Petersen’s clinical interests include treating and preventing cervical, endometrial, ovarian, vaginal, and vulvar cancers, targeted treatments, minimally invasive surgery, complementary and alternative medicine incorporation into Western Medicine, and holistic oncology care.“I will be with you during the hard times and celebrate the successes. You will be cared for. I am passionate about shared decision-making. Empowering you with as much information as you would like and any additional information I think you should know. I believe in Individualized patient care and listening to what my patients need.”When not in the office, Dr. Petersen enjoys spending her time in the mountains with her family. Dr. Petersen is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Ovarian Carcinosarcoma, Colonoscopy, and Bladder Reconstruction. Dr. Petersen is board certified in American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. Dr. Petersen is currently accepting new patients.
St. Vincent Regional Hospital - Cancer Centers Of Montana
Dr. Connor completed an undergraduate degree in Biochemistry at the University of Virginia and later earned her Medical Doctorate at the University of Virginia School of Medicine. She then completed her Obstetrics & Gynecology Residency training at Brown University and Gynecologic Oncology fellowship training at the Cleveland Clinic. She is board-certified in both obstetrics and gynecology and gynecologic oncology. Her clinical interests include preventing, diagnosing, and treating ovarian, uterine, cervical, vaginal and vulvar cancers. Dr. Connor moved to Montana to ensure comprehensive access to gynecologic oncology services in the region.“I care deeply for my patients and work hard for them to have the highest level of care and autonomy in their care.”When not seeing patients, Dr. Connor spends her time with her husband, two children, and two family dogs. They spend most of their time outside, whether skiing, hiking, or catching a soccer game. Dr. Connor is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Bladder Reconstruction, and Hysterectomy. Dr. Connor is board certified in American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. Dr. Connor is currently accepting new patients.
Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.
For more advanced stage tumors, the outlook is less positive.
Background: \- Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They are interested i...
Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...
Published Date: May 01, 2026
Published By: Warren Brenner, MD, Oncologist, Lynn Cancer Institute, Boca Raton, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, eds. DiSaia and Creasman Clinical Gynecologic Oncology. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 10.
Einhorn LH. Testicular cancer. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 185.
Friedlander TW, Small E. Testicular cancer. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 83.
Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 4th ed. Philadelphia, PA: Elsevier; 2024:chap 165.
Stephenson AJ, Gilligan TD. Neoplasms of the testis. In: Dmochowski RR, Kavoussi LR, Peters CA, et al, eds. Campbell-Walsh-Wein Urology. 13th ed. Philadelphia, PA: Elsevier; 2026:chap 79.